<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed <z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(q15;q11.2) originally present in the patient, analysis of which may facilitate identification of gene target(s) of recurrent 6q rearrangements in B-cell <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Our findings are discussed in light of the current understanding of endemic and <z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>BLUE-1 grows well in culture and should be a useful <z:hpo ids='HP_0002665'>lymphoma</z:hpo> research tool </plain></SENT>
</text></document>